Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Form 8.3 - Cyprotex PLC

5 Aug 2016 09:32

RNS Number : 3926G
Richard John Koch
05 August 2016
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Richard John Koch

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Cyprotex

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

4th August 2016

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

842 056

3.75%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

842 056

3.75%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

1p ordinary

 

sale

400 000

143.00p

 

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

5th August 2016

Contact name:

Ricardo Santos

Telephone number:

+351 927 597 796

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETVELBBQVFXBBF
Date   Source Headline
7th Apr 20164:11 pmRNSForm 8.3 - Cyprotex PLC
7th Apr 20161:42 pmRNSForm 8.3 - Cyprotex
7th Apr 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Apr 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Apr 20163:10 pmRNSForm 8.3 - Cyprotex PLC
5th Apr 20169:30 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201612:36 pmBUSForm 8.3 - Cyprotex Plc
4th Apr 201612:01 pmRNSForm 8.3 - Cyprotex plc
4th Apr 201610:32 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201610:31 amPRNForm 8.3 - Cyprotex Plc
1st Apr 20163:58 pmRNSForm 8.3 - Cyprotex Plc
1st Apr 20167:02 amRNSStrategic Review
1st Apr 20167:01 amRNSNotice of General Meeting
1st Apr 20167:00 amRNSFinal Results
31st Mar 201610:58 amRNSLaunch of Advanced 3D Liver Model
29th Mar 20167:00 amRNSChanges to UK reporting framework
9th Mar 20167:00 amRNSLaunch of New Chemical and Cosmetics Testing Guide
10th Feb 20167:00 amRNSStrategic partnering deal with Cytocentrics
21st Jan 20167:00 amRNSExecutive Option Scheme
17th Dec 20159:09 amRNSTrading Update
17th Nov 20157:00 amRNSLaunch of Solution to Predict Preclinical Toxicity
23rd Oct 20157:00 amRNSTrading Update
15th Oct 20157:00 amRNSLaunch of New ADME Guide
13th Oct 20157:00 amRNSPartnership in the EC funded EU-ToxRisk consortium
8th Oct 20157:00 amRNSConversion of Loan Notes, Directors Dealing & TVR
21st Sep 20158:40 amRNSHolding(s) in Company
19th Aug 201512:02 pmRNSHolding(s) in Company
18th Aug 20157:00 amRNSInterim Results 2015
16th Jul 20157:00 amRNSLaunch of new Biosciences division
14th Jul 20157:00 amRNSLaunch of new chemPK workflow solution
10th Jul 201510:32 amRNSHolding(s) in Company - REPLACEMENT
10th Jul 201510:29 amRNSHolding(s) in Company - REPLACEMENT
9th Jul 20151:01 pmRNSHolding(s) in Company
9th Jul 20151:00 pmRNSHolding(s) in Company
17th Jun 201510:26 amRNSResult of AGM
1st Jun 20157:00 amRNSTrading Update
22nd May 20157:00 amRNSPublication of Annual Report & Notice of AGM
6th May 20157:02 amRNSHolding(s) in Company
15th Apr 20157:00 amRNSFinal Results
14th Apr 20157:00 amRNSLaunch of in vitro service using 3D microtissues
31st Mar 20157:00 amRNSLaunch of new laboratory in its US facility
19th Mar 20157:00 amRNSLaunch of Short Time Exposure Service
12th Mar 20157:00 amRNSAppointment of Leader of Drug Transporter Team
22nd Dec 201412:12 pmRNSDirector Dealing
19th Nov 20141:26 pmRNSDirector Dealing 19 November 2014
14th Nov 20143:34 pmRNSDirector Dealing 14 November 2014
14th Nov 20147:00 amRNSTrading Update
13th Nov 20145:17 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSEnhanced SenCeeTox® technology
13th Oct 20142:14 pmRNSConversion of Loan Notes & TVR (Replacement)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.